MX2023000511A - Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones. - Google Patents

Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones.

Info

Publication number
MX2023000511A
MX2023000511A MX2023000511A MX2023000511A MX2023000511A MX 2023000511 A MX2023000511 A MX 2023000511A MX 2023000511 A MX2023000511 A MX 2023000511A MX 2023000511 A MX2023000511 A MX 2023000511A MX 2023000511 A MX2023000511 A MX 2023000511A
Authority
MX
Mexico
Prior art keywords
lungs
lipid nanoparticles
delivering therapeutics
therapeutics
delivering
Prior art date
Application number
MX2023000511A
Other languages
English (en)
Spanish (es)
Inventor
James Heyes
Kieu Mong Lam
Lorne Ralph Palmer
Original Assignee
Genevant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genevant Sciences Gmbh filed Critical Genevant Sciences Gmbh
Publication of MX2023000511A publication Critical patent/MX2023000511A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2023000511A 2020-07-10 2021-07-08 Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones. MX2023000511A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063050594P 2020-07-10 2020-07-10
PCT/US2021/040913 WO2022011156A1 (en) 2020-07-10 2021-07-08 Lipid nanoparticles for delivering therapeutics to lungs

Publications (1)

Publication Number Publication Date
MX2023000511A true MX2023000511A (es) 2023-02-13

Family

ID=79552114

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023000511A MX2023000511A (es) 2020-07-10 2021-07-08 Nanoparticulas lipidicas para administrar agentes terapeuticos en los pulmones.

Country Status (10)

Country Link
US (1) US20240065982A1 (cg-RX-API-DMAC7.html)
EP (1) EP4178585A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023534206A (cg-RX-API-DMAC7.html)
KR (1) KR20230038217A (cg-RX-API-DMAC7.html)
CN (1) CN115768438A (cg-RX-API-DMAC7.html)
AU (1) AU2021305214A1 (cg-RX-API-DMAC7.html)
CA (1) CA3188661A1 (cg-RX-API-DMAC7.html)
IL (1) IL299750A (cg-RX-API-DMAC7.html)
MX (1) MX2023000511A (cg-RX-API-DMAC7.html)
WO (1) WO2022011156A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019376006B2 (en) 2018-11-09 2026-07-02 Arbutus Biopharma Corporation Cationic lipids containing silicon
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
US12011507B2 (en) 2022-04-01 2024-06-18 Nanovation Therapeutics Inc. MRNA delivery composition
WO2024086929A1 (en) * 2022-10-25 2024-05-02 Nanovation Therapeutics Inc. Lipid nanoparticle formulations for anti-sense oligonucleotide delivery
WO2025133951A1 (en) * 2023-12-21 2025-06-26 Genevant Sciences Gmbh Ionizable lipids suitable for lipid nanoparticles
AU2025217182A1 (en) 2024-02-02 2026-08-06 Editas Medicine, Inc. MODIFIED GUIDE RNAs
WO2025213138A1 (en) 2024-04-05 2025-10-09 Editas Medicine, Inc. Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma
CN118576568B (zh) * 2024-08-06 2024-11-26 北京悦康科创医药科技股份有限公司 一种药物组合物及其制备方法和应用
CN121622610A (zh) * 2024-09-05 2026-03-10 苏州慧疗生物医药科技有限公司 向细胞内递送遗传物质的三组分脂质纳米颗粒及组合物
WO2026102260A1 (en) 2024-11-08 2026-05-15 Editas Medicine, Inc. Crispr-related methods and compositions targeting angiopoietin like 3 (angptl3)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2279254B1 (en) * 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
ES2898340T3 (es) * 2015-07-09 2022-03-07 Insmed Inc Composiciones y métodos para tratar neumopatías y lesión pulmonar
GB2596224B (en) * 2018-06-19 2022-09-07 Univ Texas Lipid nanoparticle compositions for delivery of mRNA and long nucleic acids
DE102018127300A1 (de) * 2018-10-31 2020-04-30 Henkel Ag & Co. Kgaa Wirkstoffzusammensetzung zum Schutz künstlich gefärbter Haare
AU2019376006B2 (en) * 2018-11-09 2026-07-02 Arbutus Biopharma Corporation Cationic lipids containing silicon
WO2020219941A1 (en) * 2019-04-26 2020-10-29 Genevant Sciences Gmbh Lipid nanoparticles

Also Published As

Publication number Publication date
WO2022011156A1 (en) 2022-01-13
AU2021305214A1 (en) 2023-02-23
EP4178585A1 (en) 2023-05-17
JP2023534206A (ja) 2023-08-08
KR20230038217A (ko) 2023-03-17
CA3188661A1 (en) 2022-01-13
CN115768438A (zh) 2023-03-07
WO2022011156A9 (en) 2022-03-17
US20240065982A1 (en) 2024-02-29
IL299750A (en) 2023-03-01
EP4178585A4 (en) 2024-11-20

Similar Documents

Publication Publication Date Title
WO2022032154A3 (en) Compositions for the delivery of payload molecules to airway epithelium
ZA202103233B (en) Lipid nanoparticle formulations
PH12022550363A1 (en) Improved lipid nanoparticles for delivery of nucleic acids
ZA202106265B (en) Compositions and methods for inhibiting gene expression of lpa
EP4178585A4 (en) LIPID DNA PARTICLES FOR DELIVERY OF THERAPEUTICS TO THE LUNGS
MX2024013597A (es) Composiciones de nanoparticulas lipidicas para suministro de agentes biologicamente activos
MX2022007680A (es) Nanoparticulas lipidicas para administracion de acidos nucleicos.
WO2020051220A8 (en) Compositions and methods for organ specific delivery of nucleic acids
NZ718817A (en) Lipid formulations for delivery of messenger rna
MX354618B (es) Sistema de nanopartículas nts-poliplex para terapia génica de cáncer.
PH12020550195A1 (en) Use of p38 inhibitors to reduce expression of dux4
ZA202403360B (en) Lipid nanoparticles for oligonucleotide delivery
BR112018070361A2 (pt) redução da carga tumoral através da administração de antagonistas do ccr1 em combinação com inibidores de pd-1 ou inibidores de pd-l1
PH12017501501A1 (en) Compositions and methods for inhibiting expression of tmprss6 gene
MX2014004725A (es) Formulaciones de etanercept estabilizadas con aminoacidos.
MX385048B (es) Composiciones y metodos para inhibir la expresion del gen alas1.
EP4299133A3 (en) Compositions and methods for the delivery of therapeutics
UA115648C2 (uk) Доставка терапевтичних агентів до цнс
PH12019502660A1 (en) RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
BR112015029970A2 (pt) inibidores de cinase
MX2016004319A (es) Composiciones y metodos para inhibir la expresion del gen de sintasa de acido 5'-aminolevulinico 1 (alas1).
MX2024005110A (es) Nanoparticulas lipidicas para administracion de oligonucleotidos.
MX385871B (es) Composiciones y metodos para inhibir la expresion del gen lect2.
EA201591188A1 (ru) Доставка глатирамера ацетата через слизистую оболочку
HK40084784A (en) Lipid nanoparticles for delivering therapeutics to lungs